Safety Follow-up Study of Inhaled Iloprost in Patients With Pulmonary Hypertension

Open-label, Uncontrolled, Long-term Surveillance Study of Iloprost Aerosol Inhalation Therapy in the Treatment of Patients With Primary or Secondary Pulmonary Hypertension. Follow-up Program for Patients Who Completed 12 Weeks in Study ME97218/300180.

The aim of this study is to monitor long-term safety and tolerability of iloprost aerosol inhalation therapy in patients suffering from pulmonary hypertension.

This study has previously been posted by Schering AG, Germany. Schering AG has been renamed to Bayer Schering Pharma AG, Germany.

Bayer Schering Pharma AG, Germany is the sponsor of the trial.

Inclusion Criteria:

• Completion of the 12-week treatment period of the predecessor Schering study 97218/300180
• Investigator judged iloprost aerosol therapy warranted as a suitable treatment for the respective patient
• Negative pregnancy test for females

Exclusion Criteria:

• Any condition during 12-week treatment period of the predecessor Schering study 97218/300180 that prevents participation in the follow-up safety surveillance study